Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transfusion and COVID-19 (TRANSCOV-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05075915
Recruitment Status : Recruiting
First Posted : October 13, 2021
Last Update Posted : December 1, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:

Alsace was particularly and early on affected by SARS-CoV-2 and quickly implemented a reduction in scheduled admissions and non-urgent surgical interventions, making it possible to reduce requests for labile blood products linked to non-urgent surgical procedures. as has been reported in the literature; the population containment measures also led to a major reduction in traffic - and consequently accidents on the public roads. At the same time, other demands for blood products related to activities such as onco-hematology were little affected. Finally, the blood banks have adapted their collection procedure.

To answer these questions, we propose to conduct a retrospective study over two parallel periods of 2019 and 2020 of the consumption of blood products on the one hand and the availability of stocks on the other hand.


Condition or disease
COVID-19

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Transfusion and COVID-19
Actual Study Start Date : September 1, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020 [ Time Frame: Files analysed retrospectively from from February 24 to May 31, 2019 and from February 24 to May 31, 2020 will be examined] ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients (≥18 years old) admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020
Criteria

Inclusion criteria:

  • Adults patient (≥18 years old)
  • Patients admitted to Strasbourg University Hospitals for suspicion of Covid-19, between February 24 and May 31 of 2019 and 2020
  • Labile blood products consumed between February 24 and May 31 of 2019 and 2020
  • Subjects not having his opposition, after information, to the reuse of his data for the purposes of this research.

Non-inclusion criteria:

  • Patients who expressed opposition to participating in the study
  • Patients under legal protection
  • Patients under guardianship or curatorship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05075915


Contacts
Layout table for location contacts
Contact: Paul-Michel MERTES, MD, PhD 33 3 69 55 04 44 paul-michel.mertes@chru-strasbourg.fr
Contact: Saïd CHAYER, PhD, HDR said.chayer@chru-strasbourg.fr

Locations
Layout table for location information
France
Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg Recruiting
Strasbourg, France, 67091
Contact: Paul-Michel MERTES, MD, PhD    33 3 69 55 04 44    paul-michel.mertes@chru-strasbourg.fr   
Contact: CHAYER, PhD, HDR       said.chayer@chru-strasbourg.fr   
Principal Investigator: Paul-Michel MERTES, MD, PhD         
Sub-Investigator: Xavier DELABRANCHE, MD         
Sub-Investigator: François LEVY, MD         
Sub-Investigator: Anne ROCHE, MD         
Sub-Investigator: Charles TACQUARD, MD         
Sub-Investigator: Françoise BERTRAND, MD         
Sub-Investigator: Christian GACHET, MD         
Sub-Investigator: Catherine HUMBRECHT, MD         
Sub-Investigator: Daniel KIENTZ, MD         
Sub-Investigator: Pierre TRAN BA LOC, MD         
Sub-Investigator: Xavier PIVOT, MD         
Sub-Investigator: Florian SIRLIN, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Layout table for investigator information
Principal Investigator: Paul-Michel MERTES, MD, PhD Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Layout table for additonal information
Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT05075915    
Other Study ID Numbers: 7958
First Posted: October 13, 2021    Key Record Dates
Last Update Posted: December 1, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Strasbourg, France:
COVID-19
Blood donation
Blood transfusion
Labile products
Blood platelets
Psoralen
ECMO
SARS-CoV-2
Consumption of blood products
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases